Related Experiment Video
Updated: Aug 1, 2026
Preparation, Purification, and Characterization of Lanthanide Complexes for Use as Contrast Agents for Magnetic Resonance Imaging
Published on: July 21, 2011
Preclinical evaluation of Manganese-52 labelled cyclodextrin: a prostaglandin E2 affine imaging probe
Renáta Adél Dienes1, Lili Anna Komor2, Judit P Szabó2
1Gyula Petrányi Doctoral School of Clinical Immunology and Allergology, Faculty of Medicine, University of Debrecen, Nagyerdei St. 98 H-4032 Debrecen, Hungary; Division of Nuclear Medicine and Translational Imaging, Department of Medical Imaging, Faculty of Medicine, University of Debrecen, Nagyerdei St. 98 H-4032 Debrecen, Hungary.
Abstract:
Prostaglandin E2 (PGE2) is implicated in several tumor-related biological processes, making it a promising biomarker for molecular imaging. In nuclear medicine, radiolabelled cyclodextrins have emerged as potential probes to target PGE2 in various cancer types. Hereafter, we aimed to specify the pharmacokinetics of a novel Manganese-52-labelled randomly methylated β-cyclodextrin ([52Mn]Mn-DOTAGA-RAMEB) by performing multiple time-point positron emission tomography and ex vivo biodistribution studies in PGE2 positive BxPC-3 pancreatic adenocarcinoma xenografts. In line with the ex vivo findings, [52Mn]Mn-DOTAGA-RAMEB showed early and specific tumor uptake (30 and 60 min after injection), followed by rapid wash-out and renal clearance. Our experimental data demonstrate the feasibility of 52Mn-labelled RAMEB cyclodextrin to identify PGE2 expressing tumors, although further pharmacokinetic optimization is required to enhance tumor retention and fully exploit its diagnostic potential.
